Multi-Epitope Melanoma Peptide Vaccine
Malignant Conjunctival Neoplasm
Craig L Slingluff, JrvaccinePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Malignant Conjunctival Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide National Institutes of Health Clinical Center (CC) | Phase 2 | CCC |
cc-5013 National Institutes of Health Clinical Center (CC) | Phase 2 | CCC |
Tetanus Toxoid Helper Peptide Craig L Slingluff, Jr | Phase 1 | CC |
Ifa Craig L Slingluff, Jr | Phase 1 | CC |
Gm-Csf Ahmad Tarhini | Phase 1 | CC |
pf-3512676 Ahmad Tarhini | Phase 1 | CC |
Same molecule, other indications
Multi-Epitope Melanoma Peptide Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →